Journal of Psychopharmacology

Papers
(The H4-Index of Journal of Psychopharmacology is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat201
The chronic effects of a combination of herbal extracts (Euphytose ® ) on psychological mood state and response to a laboratory stressor: A randomise140
Off the RADAR; questions regarding the trial protocol of a randomised controlled trial of antipsychotic reduction and discontinuation126
The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies95
Science, safety and education: Informing the psychedelic treatment of psychiatric disorders71
Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study58
Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study53
Psychedelics and the ‘inner healer’: Myth or mechanism?52
The effects of the PDE4 inhibitor roflumilast on cognitive performance after a cerebrovascular accident: a double-blind randomized placebo-controlled trial with an open label extension (ROSTMEMA)52
Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study52
Preliminary evidence that serum interleukin-6 is a candidate biomarker of response to esketamine in treatment-resistant depression51
Cannabimimetic and discriminative stimulus effects of hexahydrocannabinols in mice51
Circadian rhythmicity in prepulse inhibition of the acoustic startle response: A study of chronotype and time-of-day effects in young healthy adults48
Effects of initial nicotine exposure on cognition and nicotine reinforcement among non-smoking young adults with and without attention deficit hyperactivity disorder47
Award winning abstracts presented at the 15 th Annual International College of Mental Health Pharmacy (CMHP) Conference, Liverpool, UK, on 10 47
Neurocognitive changes in lithium-treated older adult bipolar patients on antipsychotics46
Co-use of psychedelics with other substances: Findings from the global psychedelic survey44
Deaths related to the use of diarylethylamines, with a focus on the United Kingdom: A systematic review and case series report43
Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment41
Pharmaco-fUS in cognitive impairment: Lessons from a preclinical model41
Relationship between change in social evaluation learning and mood in early antidepressant treatment: A prospective cohort study in primary care39
Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool38
An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine37
A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy36
Comparison of average time-to-relapse following ECT versus ketamine – A systematic review36
The effects of antenatal depression and SSRI exposure on children: A systematic review36
A framework for assessment of adverse events occurring in psychedelic-assisted therapies35
The D1/D2-like receptor antagonist flupentixol and the D2-like receptor antagonist L-741626 decrease operant responding for nicotine and food and locomotor activity in male and female rats34
Associations between regular cannabis use and brain resting-state functional connectivity in adolescents and adults33
Dynamic excitatory-inhibitory differences in autistic and non-autistic adults: Evidence from a pharmacological challenge with arbaclofen32
Psychedelic research – Going global31
0.081996917724609